FACTS AND HOPES IN CANCER IMMUNOTHERAPY
Madrid. Nov. 22nd and 23rd, 2019
FRIDAY, NOVEMBER 22nd
14.20-14.30 OPENING – Esperanza Lozano. Director CUN Madrid
KEYNOTE LECTURE
Chairs: Ignacio Melero, CUN-CIMA. Francisco Sánchez-Madrid, CNIC- Hospital de La Princesa
14.30-15.05 “NK cell-based Tumor Therapies” – Lorenzo Moretta. Ospedale Pediatrico Bambino Gesù. Rome
15.05-15.15 Questions and answers
SESSION 1. CROSSPRIMING AND CANCER
Chairs: David Sancho, CNIO. Alvaro Teijeira, CIMA
15.15-15.50 “Crosspriming” – Sebastian Amigorena. Institut Curie. Paris
15.50-16.25 “Inammation and cancer immunogenicity” – Santiago Zelenay. Cancer Research UK Manchester Institute. UK
16.25-17.00 “cDC1 and hot tumors” – Jason Luke. University of Chicago Medicine. Chicago.
17.00-17.15 Questions and answers
17.15-18.00 COFFEE BREAK
SESSION 2. RADIOIMMUNOTHERAPY (Sponsored by EMD)
Chairs: Felipe Calvo, CUN. Rafael Martínez Monge, CUN
18.00-18.35 “Oligometastasis and radiotherapy” – Ralph R. Weichselbaum. University of Chicago Medicine, Chicago
18.35-19.10 “Radiotherapy and virotherapy” – Kevin Harrington. The Institute of Cancer Research, London
19.10-19.45 “Abscopal effects of radioimmunotherapy” – María Rodríguez Ruiz. CUN. Pamplona
19.45-20.00 Questions and answers
SATURDAY, NOVEMBER 23rd
SESSION 3. FACTS AND HOPES REACHING THE CLINIC (I)
Chairs: Cristina Mingari, University of Genova. Ospedale Policlinico San Martino – IRCCS. Mariano Ponz, CUN
08.30-9.05 “Immunotherapy of primary liver cancer” – Bruno Sangro. CUN. Pamplona
09.05-9.40 “Immunotherapy of colon cancer” – Guillem Argilés. Vall d’Hebron Institute of Oncology (VHIO), Barcelona
09.40-10.15 “New targets in immunotherapy: LAG3-FGL1 and SIGLEC 152” – Jun Wang. NY University
10.15-10.30 Questions and answers
10.30-11.00 COFFEE BREAK
KEYNOTE LECTURE
Chairs: Pedro Berraondo, CIMA. Noelia Casares, CIMA
11.00-11.35 “Creative biotechnology for cancer immunotherapy” – Pablo Umaña. Roche Innovation Center Zurich
11.35-11.45 Questions and answers
SESSION 4. ADOPTIVE T-CELL THERAPY (Sponsored by GILEAD)
Chairs: Juan J. Lasarte, CIMA. Paloma Sánchez-Mateos,Universidad Complutense de Madrid
11.45-12.20 “An introduction to adoptive T-Cell therapy” – Sandra Hervás. CIMA. Pamplona
12.20-12.55 “TIL Therapy” – Inge Marie Svane. University of Copenhagen. Dinamarca
12.55-13.30 “CAR T-Cell Therapy” – Marcela Maus. MGH Center for Cancer Research. Charlestown
13.30-13.45 Questions and answers
13.45-15.30 LUNCH BREAK
SESSION 5. FACTS AND HOPES REACHING THE CLINIC (II)
Chairs: Eduardo Castañón, CUN. Miguel Fernández de Sanmamed, CUN
15.30-16.05 “Immunotherapy of urogenital cancer” – José Luis Pérez Gracia. CUN. Pamplona
16.05-16.40 “Immunotherapy of ovarian cancer” – Antonio González. CUN. Madrid
16.40-17.15 “Immunotherapy of melanoma” – José María Piulats. Bellvitge Biomedical Research (IDIBELL). Barcelona
15.15-17.30 Questions and answers
17.30-18.15 ROUND TABLE “EARLY PHASE CLINICAL TRIALS IN CANCER IMMUNOTHERAPY”
Chairs:
· Ignacio Melero, CUN.
· Eduardo Castañón, CUN
Panelists:
· Emiliano Calvo, Centro Integral Oncológico Clara Campal, Madrid.
· Mariano Ponz, CUN, Pamplona.
· Elena Garralda. Vall d’Hebron Institute of Oncology (VHIO). Barcelona
· María Rodríguez Ruiz. CUN. Pamplona
· Iván Márquez Rodas. Hospital General Universitario Gregorio Marañón. Madrid
18.15-18.30 FAREWELL AND MEETING ADJOURNS
VENUE
Fundación Ramón Areces
Calle Vitruvio, 5, 28006 Madrid
SYMPOSIUM COORDINATORS
Ignacio Melero, Miguel Fernández de Sanmamed,
Pedro Berraondo, Eduardo Castañón, María Rodríguez Ruiz
REGISTRATIONS
https://cancerimmunotherapyday-cun.com